Objective: The objective was to determine the impact of the coexpression of epidermal growth factor receptor (EGFR) and tumor marker c-erbB-2 on disease-free survival (DFS) and pelvic relapse-free survival (PRFS) in patients with locally advanced cervical cancer (LACC) receiving concurrent chemoradiotherapy. Methods: The expression of EGFR and c-erbB-2 was assessed by immunohistochemistry, which was centralized and blinded to outcome. Univariate and multivariate analyses were used to evaluate the impact of EGFR and c-erbB-2 on DFS and PRFS. Results: 170 patients with LACC were included and received concurrent chemoradiotherapy. 25 (15%) biopsies were considered EGFR and c-erbB-2 positive; 100 (59%) were either EGFR or c-erbB-2 positive, and 45 (26%) were EGFR and c-erbB-2 negative. The 3- and 5-year DFS was 39% each for EGFR- and c-erbB-2-positive patients, 54 and 49%, respectively, for EGFR- or c-erbB-2-positive patients, and 76 and 72%, respectively, for EGFR- and c-erbB-2-negative patients (p = 0.006). EGFR- and c-erbB-2-positive tumors were significantly associated with a decrease in PRFS (hazard ratio, HR, 3.99; 95% confidence interval, CI, 1.44–11.05, p = 0.007), and DFS (HR 2.9; 95% CI, 1.26–6.66, p = 0.01). Conclusion: Patients with LACC coexpressing EGFR and c-erbB-2, and treated with concurrent chemoradiotherapy, had a worse clinical prognosis with shorter DFS and PRFS.

Keywords:
Cervical cancer, c-erbB-2, Epidermal growth factor receptor, Heterodimerization, Pelvic relapse-free survival
1.
Gaffney DK, Haslam D, Tsodikov A, Hammond E, Seaman J, Holden J, Lee RJ, Zempolich K, Dodson M: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:922–928.
2.
Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL: Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 1993;46:149–153.
3.
Hayashi Y, Hachisuga T, Iwasaka T, Fukuda K, Okuma Y, Yokoyama M, Sugimori H: Expression of ras oncogene product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement. Gynecol Oncol 1991;40:147–151.
4.
Hove MG, Dinh TV, Hannigan EV, Lucci JA 3rd, Chopra V, Smith ER, To T: Oncogene expression and microvessel count in recurrent and nonrecurrent stage IB squamous cell carcinoma of the cervix. J Reprod Med 1999;44:493–496.
5.
Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, Van de Vijver MJ: Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999;5:577–586.
6.
Kim YT, Park SW, Kim JW: Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol 2002;87:84–89.
7.
Kristensen GB, Holm R, Abeler VM, Trope CG: Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996;78:433–440.
8.
Lee CM, Lee RJ, Hammond E, Tsodikov A, Dodson M, Zempolich K, Gaffney DK: Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol Oncol 2004;93:209–214.
9.
Nagai N, Oshita T, Fujii T, Kioka H, Katsube Y, Ohama K: Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer. Oncol Rep 2000;7:551–559.
10.
Ngan HY, Cheung AN, Liu SS, Cheng DK, Ng TY, Wong LC: Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis. Tumour Biol 2001;22:176–183.
11.
Pfeiffer D, Stellwag B, Pfeiffer A, Borlinghaus P, Meier W, Scheidel P: Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1989;33:146–150.
12.
Scambia G, Ferrandina G, Distefano M, D’Agostino G, Benedetti-Panici P, Mancuso S: Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Lett 1998;123:135–139.
13.
Costa MJ, Walls J, Trelford JD: c-erbB-2 oncoprotein overexpression in uterine cervix carcinoma with glandular differentiation: a frequent event but not an independent prognostic marker because it occurs late in the disease. Am J Clin Pathol 1995;104:634–642.
14.
Hale RJ, Buckley CH, Fox H, Williams J: Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol 1992;45:594–596.
15.
Kihana T, Tsuda H, Teshima S, Nomoto K, Tsugane S, Sonoda T, Matsuura S, Hirohashi S: Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994;73:148–153.
16.
Mandai M, Konishi I, Koshiyama M, Komatsu T, Yamamoto S, Nanbu K, Mori T, Fukumoto M: Altered expression of NM23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer 1995;75:2523–2529.
17.
Nakano T, Oka K, Ishikawa A, Morita S: Correlation of cervical carcinoma c-erbB-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 1997;79:513–520.
18.
Ndubisi B, Sanz S, Lu L, Podczaski E, Benrubi G, Masood S: The prognostic value of HER-2/neu oncogene in cervical cancer. Ann Clin Lab Sci 1997;27:396–401.
19.
Nevin J, Laing D, Kaye P, McCulloch T, Barnard R, Silcocks P, Blackett T, Paterson M, Sharp F, Cruse P: The significance of erb-B2 immunostaining in cervical cancer. Gynecol Oncol 1999;73:354–358.
20.
Niibe Y, Nakano T, Ohno T, Suzuki Y, Oka K, Tsujii H: Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. Int J Gynecol Cancer 2003;13:849–855.
21.
Oka K, Nakano T, Arai T: c-erbB-2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 1994;73:664–671.
22.
Wong YF, Chung TK, Cheung TH, Lam SK, Tam OS, Lu HJ, Xu FD, Chang AM: HER-2/neu gene amplification in cervical cancer in Chinese women of Hong Kong and China. J Obstet Gynaecol Res 1996;22:171–175.
23.
Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Holscher AH, Danenberg PV: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850–1855.
24.
Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS: Expression profiles of erbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001;7:1957–1962.
25.
DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D 2nd, Thor AD: Relationship of epidermal growth factor receptor expression to erbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005;23:1152–1160.
26.
Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C: Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 1989;34:123–131.
27.
Lee JC, Wang ST, Chow NH, Yang HB: Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002;38:1065–1071.
28.
Tateishi M, Ishida T, Kohdono S, Hamatake M, Fukuyama Y, Sugimachi K: Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol 1994;3:109–113.
29.
Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, Li L, Katz RL, Hung MC: Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999;5:4164–4174.
30.
NCI issues clinical announcement on cervical cancer: chemotherapy plus radiation improves survival. Bethesda, United States Department of Health and Human Services, 1999.
31.
Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, Tsurumaru M, Sasai K: c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2003;57:1323–1327.
32.
Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884–2890.
33.
Giralt J, de las Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, Lujan J, Espin E, Rosello J, Majo J, Benavente S, Armengol M, de Torres I: The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 2005;74:101–108.
34.
Sheridan MT, O’Dwyer T, Seymour CB, Mothersill CE: Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 1997;5:180–186.
35.
Scambia G, Benedetti-Panici P, Ferrandina G, Distefano M, Salerno G, Romanini ME, Fagotti A, Mancuso S: Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 1995;72:361–366.
36.
Tsai CM, Chang KT, Li L, Perng RP, Yang LY: Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn J Cancer Res 2000;91:213–222.
37.
Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y: Differential endocytic routing of homo- and hetero-dimeric erbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 1998;17:3385–3397.
38.
Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG, Dobashi K, Greene MI: Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 1989;58:287–292.
39.
Cohen BD, Green JM, Foy L, Fell HP: HER4-mediated biological and biochemical properties in NIH3T3 cells. Evidence for HER1-HER4 heterodimers. J Biol Chem 1996;271:4813–4818.
40.
Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 1988;80:1605–1611.
41.
Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991;51:4575–4580.
42.
Fan Z, Baselga J, Masui H, Mendelsohn J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well-established a431 cell xenografts. Cancer Res 1993;53:4637–4642.
43.
Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6:701–708.
44.
Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A: Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568–5577.
45.
Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803–1810.
46.
Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053–2063.
47.
Diermeier S, Horvath G, Knuechel-Clarke R, Hofstaedter F, Szollosi J, Brockhoff G: Epidermal growth factor receptor coexpression modulates susceptibility to herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005;304:604–619.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.